Photo Release: The Hemophilia treatment NHSO-project Reduce rate of hospital administration

Food and Healthcare Press Releases Monday October 2, 2017 14:20
Bangkok--2 Oct--Core & Peak

Recently, Dr.Chuchai Sornchamni, Deputy Secretary-General of the National Health Security Office (NHSO) (right) together with Prof. Dr. Ampaiwan Prachamrit, Director of the Hemophilia International Blood Transfusion Training Center - Bangkok Faculty of Medicine, Ramathibodi Hospital (left) give the special press interview on " 10 years of the Hemophilia treatment" NHSO's Project at Centara Grand at Central World, Bangkok.–Since 2006 the NHSO has continually provided hemophilia patients access to drug including home care which allow patients to have immediate access to drug at home which consequently reduce the number of in-hospital stays and outpatient visits. The project is clearly shows to save health care cost and improve health outcome for Thai hemophilia patients.


Latest Press Release

ESMO Publishes New Position Paper on Supportive and Palliative Care

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757 ], calling attention to the evolving and growing gap between the needs of cancer...

Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

The medical device company is transforming neurological treatments through its non-invasive focused ultrasound applications Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies,...

MediaTek Sensio: New Biosensor Solution Brings Health Monitoring to Smartphones

MediaTek Inc. today unveiled MediaTek Sensio(TM), the first 6-in-1 smartphone biosensor module. MediaTek Sensio is a powerful advanced health monitoring solution which makes it easy to track heart rate information, blood pressure trends, peripheral...

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Related Topics